The Future Shape of Blood Collection Tubes Market

No matter how large a leap we may take in diagnostics, even the best diagnostic tests fail to deliver accurate results if the biological sample isn’t well preserved. This especially applies to blood samples as blood analysis is still an important part of diagnostics. However, it wasn’t until the introduction of evacuated blood collection tubes market that several diagnostic processes became faster and more precise. In the years that followed, several improvements have been made to tube materials, the additives used to perform specific functions on blood samples, and the overall design of such tubes.

North America has been at the forefront of several new developments reported in the global blood collection tubes market. According to a Transparency Market Research report, the North America blood collection tubes market is on course to reach a valuation of US$632.1 mn by 2023. The market approximated US$300.8 mn in 2014, the report says.

Request Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=8689

Here are the top five highlights of the blood collection tubes market in North America

• The volume of blood collected in North America every year for medical purposes is staggering. In the United States alone, estimates show that over 18 mn units of blood is transfused annually to treat hematologic diseases.
• Tests on blood samples are vital to the timely diagnosis of potentially life-threatening diseases such as dengue, thalassemia, and even certain types of cancer. This is causing an uptick in the demand of blood collection tubes.
• The coverage of several diseases and conditions under new reimbursement plans in the United States has caused a spurt in the number of diagnostic tests conducted here annually, subsequently leading to higher demand for blood collection tubes.
• By type, the blood collection tubes market can be divided into rapid serum tubes, plasma separating tubes, heparin tubes, serum separating tubes, and other tubes. Of these, North America sees the highest demand for serum separating tubes. Canada and the United States are the two key markets in North America, of which the United States blood collection tubes market generates the highest revenue.
• There is a growing demand for tubes that are compatible with automated blood collection processes and more advanced screening tests. This is prompting manufacturers to improve the design of their existing products and bring easy-to-use blood collection tubes to the market.

However, the growth of the market will likely be restricted by to some degree by the high cost of investing in sophisticated blood testing equipment. Since the safety mechanism of blood collection tubes is of utmost importance, products with the highest safety specifications will naturally hold a competitive advantage over their counterparts on the market. Some of the leading companies in the North America blood collection tubes market are Becton, Dickinson & Company (U.S.), Sarstedt AG & Co. (Germany), Greiner Group AG (Austria), Terumo Corporation (Japan), QIAGEN N.V. (Germany), and FL Medical srl (Italy).

Dyslipidemia Drugs Market Offering High-growth Opportunities for Market Players

The research report, titled “Dyslipidemia Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023,” states that the impending patent expiry of blockbuster dyslipidemia drugs is likely to dilute profit margins of drugmakers in this market. This factor is expected to influence the global dyslipidemia drugs market negatively over the forecast period, resulting in a decline in its market valuation.

Transparency Market Research (TMR) has recently published a market study on the global market for dyslipidemia drugs and projected that this market will decline at a CAGR of 10.30% during the period from 2015 to 2023.The worldwide dyslipidemia drugs market stood at US$17.9 bn in 2014. Analysts at TMR estimate the overall value of the market to reach US$6.9 bn by the end of the forecast period.

The delay in the approval of new dyslipidemia drugs is also projected to hamper the growth of this market significantly in the coming years. However, the increasing patient pool, suffering from an excess of cholesterol and other defects caused by triglyceride, is likely to drive the demand for dyslipidemia drugs in the near future, states the study.

Request A Sample Of This Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1535

Bile acid resins, statins, niacins, omega-3 fatty acid derivatives, fibric acid, cholesterol absorption inhibitors, and combination drugs are the major therapeutics available in the global dyslipidemia drugs market. As per the report, the statins segment led the overall market in 2014 and is projected to retain its position during the forecast period.

The report segments the global market for dyslipidemia drugs into Europe, Asia Pacific, North America, Latin America, and the Middle East and Africa. North America among all, dominated the worldwide dyslipidemia drugs market in 2014. Favorable government policies for drug approval in this region, together with the continual rise in the prevalence of dyslipidemia, have substantially propelled the North America market for dyslipidemia drugs.

The same year, Europe occupied the second position in the worldwide dyslipidemia drugs market with a share of around 25%. The higher disposable income of consumers in the region allows them to afford branded formulation. This in turn provides favorable growth opportunities to drug manufacturers, in this regional market, states the report.

In Europe, Germany was the biggest domestic dyslipidemia drugs market in 2014. It is likely to maintain its dominance over the forecast period, owing to the increasing incidence of dyslipidemia, resulting in the high demand for dyslipidemia drugs.

Abbott Laboratories, Amgen Inc., AstraZeneca Plc, Bayer AG, Mylan N.V., Bristol-Myers Squibb Co., Novartis AG, Pfizer Inc., Merck & Co. Inc., Shionogi & Co. Ltd., Teva Pharmaceutical Industries Ltd., and Takeda Pharmaceutical Co. Ltd. are some of the major participants in the global dyslipidemia drugs market, mentioned in this report.

Endocrine testing market - Worldwide Market Shares, Strategies, and Forecasts 2015 to 2023

The endocrine system is made up of several glands such as pineal, pituitary, and thyroid and secretory organs such as hypothalamus and pancreas. These glands secrete hormones such as luteinizing hormone (LH), insulin, follicle stimulating hormone (FSH), and estradiol directly into the blood stream for the proper regulation of a number of bodily functions such as growth and homeostasis. Endocrine testing is done on biological samples to regulate the levels of endocrine hormones and to detect any deviation in hormone production. Less secretion (hyposecretion) or excess secretion (hypersecretion) can lead to a number of endocrine disorders such as menopause, infertility, and thyroid dysfunction.

Business intelligence firm Transparency Market Research, in a recent publication, states that the global endocrine testing market is anticipated to expand at a healthy CAGR of 8.50% from 2015 to 2023, rising from a value of US$6.1 bn in 2014 to US$12.8 bn in 2023.

Breakthrough Made by Scientists at Glasgow University Could Mean Better Endocrine Testing

A major discovery made by a team of researchers in the United Kingdom is believed to have the potential for improved endocrine testing and the testing and treatment of pancreatic cancer. According to the American Cancer Society, pancreatic cancer is one of the biggest health concerns in America, with over 48,000 Americans diagnosed with the disease last year.

Scientists at the University of Glasgow have discovered that pancreatic cancer is actually four separate diseases and each one requires different diagnoses and therapies. The scientists found that there are four primary genetic errors – classified as pancreatic progenitor, squamous-type, aberrantly differentiated endocrine exocrine, and immunogenic – that have resulted in the growth of tumors in the 456 patients studied in the experiment. The discovery of these errors, researchers believe, will be able to help speed up efforts in the development of newer forms of pancreatic cancer treatment.

Request a Sample of This Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1645

Adoption of Tele-health Services to Fuel the Growth of Global Endocrine Testing Market

By type, the global endocrine testing market can be categorized into thyroid stimulating hormone (TSH) test, human chorionic gonadotropin (HCG) test, dehydroepiandrosterone sulfate (DHEAS) test, testosterone test, progesterone test, prolactin test, estradiol (E2) test, insulin test, follicle stimulating hormone (FSH) test, cortisol test, luteinizing hormone (LH) test, and others (such as thymosin, gastrin, secretin). The thyroid stimulating hormone (TSH) segment accounts for the highest share in the overall endocrine testing market, whereas insulin testing is expected to grow at a fast pace in the coming years. By technology, the global endocrine testing market can be classified into sensor, immunoassay, monoclonal and polyclonal antibody, clinical chemistry technologies, tandem mass spectrometry, and others. In 2014, the immunoassay technologies segment led the overall endocrine testing market, whereas the tandem mass spectrometry segment is projected to grow rapidly in the next few years.

By end use, the global market for endocrine testing can be segmented into home-based tests, ambulatory care centers, hospitals, physician offices, and commercial laboratories. Among these segments, commercial laboratories hold the biggest market share in the global endocrine testing market due to the presence of skilled and dedicated laboratory personnel, increased use of specialized diagnostics tools, and swift diagnostics facilities, which is propelling the global endocrine market. The introduction of tele-health services is one of the major factors projected to fuel the commercial laboratories segment in the coming years. On the other hand, the home-based tests segment is expected to register the highest growth in the next few years, owing to easy operation and the instant result of the test kits.

Endocrine Testing Market: Oligopolistic Nature of Competitive Landscape

 By nature, the competitive landscape of the global endocrine testing market is immensely oligopolistic with the top five vendors making up a whopping 90% of the overall market. In 2014, F-Hoffman La Roche Ltd. dominated the scene with a share of 23.10% in the global market, driven by increased market penetration and a wide product portfolio. Abbott Laboratories came in second with a share of 19.30% in 2014, fueled by a broad range of technological platforms. DiaSorin, Agilent Technologies, and Siemens Healthcare followed next with a share of 16.80%, 15.40%, and 13.80% respectively. These companies are propelled by the presence of a broad array of endocrine testing technologies and products. Accounting for a combined share of 11.60% in the overall revenue in 2014 were players such as Bio Rad Laboratories, AB SCIEX LLC, Sysmex Corporation, Lab Corporation, Quest Diagnostics, Biomedical Diagnostics, Ortho-clinical Diagnostics, Thermo Fisher Scientific, and bioMerieux.

How will be Demands of Global Defibrillators in Coming Future?

A defibrillator device depolarizes a critical part of a heart muscle thereby helping in restoration of normal heart rhythm. If SCA victims receive cardiopulmonary resuscitation (CPR) and defibrillation within 5 to 12 minutes of cardiac arrest, many lives can be saved. Growing incidences of cardiovascular disease and increasing healthcare infrastructure in the Middle East and Africa are the major factors expected to boost the growth in demand for defibrillators in the region. However, despite an excellent market opportunity in the Middle East and Africa, lack of awareness pertaining to operating of a defibrillator during emergency and unfavorable government intervention to install automated external defibrillators (AEDs) in public places are the key restraints for the growth of market in the Middle East and Africa. The Middle East and Africa defibrillators market was valued at USD 209.6 million in 2013 and is expected to reach an estimated value of USD 347.8 million by 2020, growing at a CAGR of 7.6%.

The Middle East and Africa defibrillators market has been segmented on the basis of product type, by end-users and by geography. On the basis of defibrillator type, the market is categorized into automated external defibrillators (AEDs) and advanced life support (ALS) defibrillators. Advanced life support defibrillators are used by medical and paramedical professionals, and emergency medical team. These defibrillators are also called as monitor/defibrillators since they possess an ability to monitor different kinds of bodily functions such as blood oxygen levels, pulse and heart rhythm. In 2013, the ALS defibrillators market accounted for the largest share by revenue in the market. The Middle East and Africa defibrillators market has also been segmented by end-user into hospitals, public access, emergency medical services and business workplaces. The defibrillators market in the region was dominated by hospitals as an end-user category accounting for more than 80% of the total market. Such high demand for defibrillators from hospitals is due to the continuous demand for ALS defibrillators as well as installation of AEDs at large hospitals.

Request A Sample Of This Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=4459

User-friendliness of New Devices Increasing Scope of Defibrillators Market in Middle East and Africa

The main restraint on the Middle East and Africa defibrillators market is the language barrier presented by the entry of Western defibrillator devices, which are accompanied by English manuals and other on-device instructions. While this may seem like a petty issue, the language barrier in the stronghold of the Arabian language is quite strong and has caused indigenous end users to reject these devices. However, taking note of this issue, many manufacturers have started incorporating instructions in the local languages on defibrillator devices, increasing the scope for the market in the forecast period. Many devices now also come equipped with audio or video assistance in the local language.

There have been numerous product recalls in the Middle East and Africa defibrillators market in the recent past, due to the language barrier as well as technical issues. This has created a skeptical attitude among the end users of defibrillators in the Middle East and Africa, including hospitals and government agencies responsible for the regulatory legislation regarding medical devices. Lack of strong government support for this crucial medical equipment is a major restraining factor for the Middle East and Africa defibrillators market.

The growing incidence of SCD, as mentioned before, is the prime growth driver for the Middle East and Africa defibrillator market and is largely responsible for the reducing importance of the language barrier. The need to have a defibrillator device handy in hospitals around the region has steadily but surely eroded the language barrier and skeptical mindset regarding defibrillators and has made the government and medical practitioners rethink their position. This will help the Middle East and Africa defibrillators market gain a stronger position in the next few years.

Automated External Defibrillators to Lead MEA Defibrillators Market in Forecast Period

There are two major types of defibrillator devices in the Middle East and Africa defibrillator market: Advanced life support (ALS) defibrillators and automated external defibrillators (AED). Advanced life support defibrillators, which need to be used in a hospital setting due to their complicated nature, led the market in 2013, but AEDs are expected to come to the fore in the forecast period.

AEDs are designed to be used by the first person to encounter the patient, regardless of the person’s medical training. This enhances the functionality of defibrillators as emergency life support devices and is expected to drive the market for the same.

According to end use, hospitals and emergency medical services are the significant segments of the Middle East and Africa defibrillators market. Others end-use segments such as public places and workplaces are expected to grow by a much smaller degree in the forecast period. A major caveat to this is linked with the increasing demand for automated external defibrillators. If governments in the Middle East and Africa encourage the installation of defibrillators in public places, this would greatly help the market for AEDs.

Things to know about Disposable Pain Pumps Market

A featured report, titled “Disposable Pain Pumps Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019,” from Transparency Market Research (TMR) offers a 360-degree view of the market. The report offers an extensive coverage of the key trends and their impact on the global disposable pain pumps market.

Pain pumps/intrathecal drug delivery is a technique of delivering medication, such as delivering an opioid directly to the spinal cord. A pain pump system consists of a small pump placed surgically under the abdominal skin. This pump delivers the drug using a catheter to the area around the spinal cord. These pumps are used when all other traditional methods have failed to provide relief to patients suffering from chronic pain. With the pain relief drug delivered directly to the spinal cord, the amount of dose required is much lower as compared to that of oral medication.

Disposable pain pumps can be programmed to release small doses of medication over a period of time. Furthermore, they can also be programmed to provide the pain relief medication in varying amount at different times of the day as per the needs of the patient. A pain pump’s reservoir can be refilled using a syringe or can be removed permanently. By application, the disposable pain pumps market is segmented into pain management and spasticity management.

Request For PDF: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1825

The global disposable pain pumps market is driven by the rising number of patients suffering from cancer pain and chronic pain. Other trends such as the significant reduction in the pain caused by failed back surgery syndrome and the rising prominence of reflex sympathetic dystrophy will also benefit the global disposable pain pumps market. In addition to this, the benefits associated with disposable pain pumps such as allowing patients the ability to perform daily activities with ease, the ease of device removal, and low medication dose are also driving the market.

According to region, the global disposable pain pumps market is segmented into Asia Pacific, Europe, North America, and Rest of the World. Currently, the global disposable pain pumps market is led by Europe and North America due to favorable trends in guidelines and protocols, clinical practice, regulatory affairs, reimbursement, and the competitive framework. Emerging economies in Latin America, Asia, and the Middle East are expected to witness high growth due to the growing awareness among consumers regarding these procedures.

The leading players operating in the global disposable pain pumps market are Alaris Medical Systems, Advanced Infusion, McKinley Medical, Sorenson Medical, Stryker, and Baxter International. Several companies in the global disposable pain pumps market have recently received approvals from the FDA. These include systems such as Medtronic’s SynchroMed(R) II Programmable Pump and Flowonix Medical’s Prometra drug delivery pump.

CEA Testing Market: Impact and Future Predictions

Carcinoembryonic antigen (CEA) is a protein produced when the fetus is developing but is absent in adults. However, the presence of CEA in abnormal amounts can lead to cancer. A CEA test is conducted to measure the level of proteins and keep a check on the recurrence of colon or other types of cancers in patients who are already diagnosed with cancer. The accepted range of this protein is between 0 and 0.25 micro-organisms per liter. Presence of CEA at an elevated level in recently treated cancer patients indicates recurrence of the ailment.

Transparency Market Research, in a new report, titled “CEA Testing Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019,” provides a comprehensive overview of the global market for CEA testing. It studies the market from the ground up, covering aspects such as the market’s definition, segmentation based on various parameters, and factors impacting its growth over the forecast period from 2013 to 2019.

The elevated levels of CEA are attributed to various types of cancers and other conditions such as heavy smoking, lung infection, cholecystitis, peptic ulcer, and inflammatory bowel disease. Additionally, hematoma, which occurs when blood accumulates under the skin, dizziness, infection, and excessive bleeding are other risks commonly associated with the presence of CEA in abnormal levels. It is possible to diagnose the level of CEA in body by using arcitumomab, which is a monoclonal antibody. Arcitumomab is also used to identify glycoprotein expression in tissue samples.

Request for Sample: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1628

In the last few years, the global market for CEA testing has exhibited impressive growth, due to the evolution of the latest technologies and the discovery of specific biomarkers and antigens. Additionally, the rising incidence of cancer and other chronic ailments has been aiding the expansion of the market as well. To provide a holistic overview, the report segments the market on the basis of instrumentation in terms of tests performed in specific regions. The future prospects of the CEA testing market have been measured by conducting a qualitative analysis on patent protection and the regulatory policies prevalent in the market.

Substantially benefitted by technological breakthroughs in genetic analysis of the disease and accuracy of diagnosis, and rigorous research and development activities, the global CEA testing market is anticipated to exhibit a positive CAGR during the report’s forecast period. The market will also gain impetus from the growing geriatric population and the subsequent rise in chronic ailments worldwide.

Despite witnessing positive growth prospects, the market’s trajectory will be inhibited due to the inadequate awareness regarding the novel technologies available in the CEA testing market. To study the market from a bird’s eye view, the report also profiles some of the leading companies operating therein such as Danaher Corporation (Beckman Coulter), Abbott Laboratories, Epigenomics, Life Technologies Corporation, Siemens Healthcare, BioMerieux, Qiagen N.V., and, Myriad Genetics.

The exhaustive information and relevant statistic compiled in the report are intended to update stakeholders about the prevalent market dynamics and assist them in determining winning strategies for the future.

A brief review of Alpha-2 Antiplasmin Market

In its report, titled “Alpha-2 Antiplasmin Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019,” Transparency Market Research (TMR) provides a professional and in-depth study on the prevailing dynamics of the global alpha-2 antiplasmin market and insights into factors that will impact the market’s growth trajectory between 2013 and 2019. The report provides a comprehensive overview of the market covering the definition of key products, classification based on various parameters, and development status of key regional markets.

Alpha-2 antiplasmin, also known as a plasmin inhibitor, is a type of glycoprotein, which is synthesized by the kidneys, liver, and other tissues of the body. It belongs to the serpin superfamily, which functions as the primary inhibitor of serine protease plasmin. Deficiency of Alpha 2 antiplasmin may cause bleeding disorders, since it increases fibrionolysis. It is responsible for inhibiting fibrinolysis and the degradation of fibrin clots. Congenital deficiency of Alpha 2 antiplasmin can also lead to internal hemorrhage. Alpha-2 antiplasmin is available in two distinct forms: non-plasminogen binding and plasminogen binding.

Download PDF: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1842

The mounting pressure for cost containment in major industrialized nations and the evolution of the latest technologies are anticipated to dramatically change coagulation testing practices in the next five years. New sensitive and specific markets for hemostasis will increasingly demand automated instrumentation. Influenced by the prevailing trends, it is very likely that Alpha-2 antiplasmin will become more standardized and offer better opportunities for quality control products and services. Additionally, the continuing contraction of hospital systems and the launch of the latest technological advances will facilitate decentralizing Alpha-2 antiplasmin testing and bring it closer to patients, thereby creating lucrative opportunities for the enterprises operating in the market to capitalize on.

The report presents a detailed overview of the global market for Alpha-2 antiplasmin across Asia Pacific, Europe, North America, and Rest of the World. Of these, North America emerged as the most lucrative market for Alpha-2 antiplasmin, since the region witnesses a rising number of metabolic syndrome cases. Research has demonstrated that the presence of Alpha-2 antiplasmin in excess is associated with cardiovascular diseases and metabolic syndrome. Deficiency of Alpha-2 antiplasmin may cause the development of atherosclerosis. According to a report published by the American Heart Association, over 35% of adults in the U.S. suffer from metabolic syndrome. This aids the expansion of the Alpha-2 antiplasmin market in North America. The market also sees favorable growth potential in Asia Pacific and Europe, since these regions witness an increasing incidence of cardiovascular diseases.